GRACEcast

Follow GRACEcast
Share on
Copy link to clipboard

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to b…

Howard (Jack) West, MD


    • Aug 25, 2016 LATEST EPISODE
    • infrequent NEW EPISODES
    • 6m AVG DURATION
    • 600 EPISODES


    Search for episodes from GRACEcast with a specific topic:

    Latest episodes from GRACEcast

    FCR vs. BR - Is One Better?

    Play Episode Listen Later Aug 25, 2016 4:23


    Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.

    Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1

    Play Episode Listen Later Aug 22, 2016 5:28


    New Trials of Targeting Therapies to Treat Leptomeningeal Carcinomatosis

    Play Episode Listen Later Aug 11, 2016 4:31


    GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss new trials of targeting therapies used to treat leptomeningeal carcinomatosis.

    ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments

    Play Episode Listen Later Aug 11, 2016 4:59


    GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss promising early results for treatments targeting new mutations.

    Immuno-oncology Developments - Combinations and Use as First-Line Therapy

    Play Episode Listen Later Aug 10, 2016 7:11


    GRACE is happy to present the 6th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss Immuno-oncology developments - combinations and use as first-Line therapy.

    Does Current Evidence Support Favoring Proton-Beam Radiation

    Play Episode Listen Later Aug 4, 2016 8:36


    GRACE is happy to present the 6th video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.   Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss whether current evidence supports favoring proton beam radiation.

    J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?

    Play Episode Listen Later Aug 4, 2016 11:02


    GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.

    Are There Less Toxic Alternatives to the Extreme Regimen

    Play Episode Listen Later Aug 3, 2016 4:06


    GRACE is happy to present the 9th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Bauml and Seiwert discuss the topic of whether there are less toxic alternatives to the extreme regimen.

    Promising Early Data for Oral Inhibitor Buparlisib

    Play Episode Listen Later Aug 3, 2016 1:55


    GRACE is happy to present the 8th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Bauml and Seiwert discuss the promising early data for the oral inhibitor Buparlisib.

    Using Immunotherapy as First-Line Treatment and in Combinations

    Play Episode Listen Later Aug 1, 2016 4:36


    7th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding ASCO 2016 HN RT-Using Immunotherapy as First-Line Treatment and in Combinations.

    Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients

    Play Episode Listen Later Jul 31, 2016 4:17


    6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients.  

    Using Biomarkers in Immunotherapy

    Play Episode Listen Later Jul 28, 2016 2:04


      GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Bauml and Seiwert discuss the using biomarkers in immunotherapy.    

    Common Side Effects of PD-1 Inhibitors

    Play Episode Listen Later Jul 19, 2016 4:16


    GRACE is happy to present the 4th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Baumi and Seiwert discuss the common side effects of PD-1 inhibitors.

    Data from Keynote 12 Nivolumab and Pembrolizumab

    Play Episode Listen Later Jul 19, 2016


    GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Baumi and Seiwert discuss the data presented from Keynote 12 - Nivolumab and Pembrolizumab. 

    How Promising Are The Results From Checkmate 141?

    Play Episode Listen Later Jul 19, 2016 2:58


    GRACE is happy to present the 2nd video in our series, ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.     Drs. Weiss, Baumi and Seiwert discuss the subject of Checkmate 141 and its results.

    Local Consolidation Therapies for Oligomatastases

    Play Episode Listen Later Jul 18, 2016


    GRACE is happy to present the 4th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of local consolidation therapies for oligomatastases.

    The Immune System and PD-1 Inhibitors

    Play Episode Listen Later Jul 15, 2016 1:45


    GRACE is happy to present the 1st video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Baumi and Seiwert discuss the subject of the immune system and PD-1 inhibitors. 

    Urine or Blood Testing Instead of Lung Biopsy Shows Promise for Finding EGFR Mutations

    Play Episode Listen Later Jul 13, 2016 8:29


    GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of urine or blood testing instead of lung biopsy, showing promise for finding EGFR mutations.     

    Can Online Patient Groups Speed New Targeted Therapies?

    Play Episode Listen Later Jul 7, 2016 4:47


    GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of online patient groups and if they can help speed the development of new targeted therapies.  A subject quite important to online groups such as our own GRACE.

    Rova-T Shows Promise in Small Cell Lung Cancer

    Play Episode Listen Later Jul 6, 2016 4:58


    1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD.  Dr. West moderates this roundtable discussion highlighting studies presented at ASCO 2016.  For this video, Rova-T is presented as showing promise in Small Cell Lung Cancer. 

    Significance Of IGHV Mutations & How They Are Assessed

    Play Episode Listen Later Jun 21, 2016 2:49


    CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed.  Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer Institute.

    Not Your Father's CLL

    Play Episode Listen Later May 25, 2016 62:15


    Faculty member Dr. John Pagel, and an in-person audience of patients and caregivers joined GRACE for 'Not Your Father's CLL', webcast LIVE from Seattle, WA on April 22, 2016. Dr. Pagel, Chief of the Hematologic Malignancies program for the expanded treatment and research of blood based cancers such as leukemia, multiple myeloma and lymphoma at Swedish Cancer Institute, spoke about current treatment options and the future of care, and took questions from both the in-person and online audiences.  We invite you to watch the video.

    Immunotherapy as First-Line Treatment

    Play Episode Listen Later Apr 26, 2016 3:46


    Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.

    Lung Cancer Screening - Process and Potential Benefits

    Play Episode Listen Later Apr 25, 2016 6:19


    Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.

    Bronchoscopy and EBUS

    Play Episode Listen Later Apr 24, 2016 5:54


    Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

    Maintenance Therapy for Advanced NSCLC

    Play Episode Listen Later Apr 21, 2016 4:35


    Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

    Play Episode Listen Later Apr 20, 2016 5:20


    Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

    Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

    Play Episode Listen Later Apr 19, 2016 3:29


    Histology-Specific Recommendations - Large-Cell Neuroendocrine

    Play Episode Listen Later Apr 18, 2016 2:24


    Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

    Histology-Specific Regimens - Squamous

    Play Episode Listen Later Apr 17, 2016 4:02


    Histology-Specific Regimens - Adenocarcinoma

    Play Episode Listen Later Apr 16, 2016 2:53


    What is the Role of Bevacizumab in Stage IV NSCLC?

    Play Episode Listen Later Apr 15, 2016 3:46


    Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

    Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment

    Play Episode Listen Later Apr 14, 2016 3:40


    Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

    Play Episode Listen Later Apr 13, 2016 2:20


    Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

    CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

    Play Episode Listen Later Apr 12, 2016 2:30


    Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

    Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

    Play Episode Listen Later Apr 11, 2016 2:00


    Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

    Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

    Play Episode Listen Later Apr 10, 2016 0:56


    Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

    ROS-1 Rearrangements: What Are They?

    Play Episode Listen Later Apr 9, 2016 1:53


    Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

    ALK Rearrangements: What Are They, and Who Has Them?

    Play Episode Listen Later Apr 8, 2016 1:47


    Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

    Multiplex Testing for Rare Mutations: What Are the Potential Benefits?

    Play Episode Listen Later Apr 7, 2016 2:56


    Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.

    The Role of Targeted Therapy Post-Resection

    Play Episode Listen Later Apr 6, 2016 4:36


    Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

    What Is a Standard Adjuvant Chemotherapy Regimen?

    Play Episode Listen Later Apr 5, 2016 4:35


    Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

    Why Give Adjuvant Chemotherapy, and to Which Patients?

    Play Episode Listen Later Apr 4, 2016 2:26


    Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.

    Zoledronate or Denosumab for Lung Cancer with Bone Metastases

    Play Episode Listen Later Mar 31, 2016 3:08


    Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer.